Congratulations to PPHM for the JMP sponsorship via report and healthcare conference. (I, of course , agree with the wag post that JPM would have been better.) JR may have a point about a possible Stifel Nicolaus report as well. Mgmt finally doing something about increased sponsorship. Will really be interested in the "percent of institutional ownership" over the next while. That's where the efficacy of all this sponsorship will show. Also, watch to see if there is a change in the quality of the buying. Does the stock do better in the pm session?? Can the stock cross the 20 day and 200 day MA's.
As an aside to mgmt and BOD, JMP recently did an IB raise of about $45mm for a small biotech. At $4-5/share they could do the same for PPHM if the company needed it.
Also, am very pleased about the presentation at the imaging conference in S.F.. I have been pushing this imaging area for a long time. There are issues about technique and cost but, people have been known to pay up for the finest things in life (see Tiffany stock and reports in a recession). If PPHM technique can become the "finest early diagnostic technique" for hard tumors, this area is big enough to become a "tail that can wag the dog" and it is absolutely getting a zero valuation re stock value. Kudos to mgmt for moving this area forward.
Lastly, have been delving more closely into the metastatic breast cancer data. IMO (really just a swag) there is a modest possiblity of a regulatory surprise after the third signal seeking test reports MOS. It is possible that the randomized, double blinded studies could be designed as a Phase IIB or Phase III requiring a second FDA meeting. This would then beg the question of vertical partnering or regional partnering to finance a larger, more complicated study, perhaps encompassing multiple combo drugs i.e. doxy , paxy, etc.. Again this is just supposition on my part. However, as the JMP analyst notes, the MOS data is "compelling" (sic).
Regards,
RRdog
